Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vertex (VRTX) PT Raised to $285 at SunTrust
January 31, 2020 6:40 AM ESTSunTrust analyst Robyn Karnauskas raised the price target on Vertex (NASDAQ: VRTX) to $285.00 (from $235.00) while maintaining a Buy rating following results.
The analyst commented, "Recent approval of VRTX's drug TRIKAFTA and strong early launch metrics de-risk CF revenues for VRTX, in our... More
Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus
January 30, 2020 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.70, $0.50 better than the analyst estimate of $1.20. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.01 billion.
"In 2019, our differentiated strategy of investing in serial scientific innovation to create transformative medicines... More
